In this episode presented by DIA, BioSpace's head of insights Lori Ellis discusses the evolution of women's inclusion in ...

The landscape of clinical trials has undergone significant changes, as highlighted in the current Series of six papers published in The Lancet Global Health. The WHO guidance provides a comprehensive ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

Modern medicine is a marvel, with previously unimaginable cures and treatments now widely available. Think of advanced ...

Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced ...

Through this agreement, Xcellbio scientists will work with the Royal Perth Hospital team to develop an automated TIL manufacturing process based on AVATAR platform that achieves key goals for cell ...

Xcell Biosciences Australia PTY LTD (Xcellbio), an affiliate of Xcell Biosciences, Inc., a platform company focused on cell and gene therapy applications, and Royal Perth Hospital announced a ...

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...

Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint ...

Tumor inflitrating lymphocyte therapies are a promising type of cellular immunotherapy used to treat a broad range of solid ...

The Clinical Trials Research Pillar in the Division of Biostatistics is at the forefront of innovative clinical trial design ...

Both companies will continue to work independently till the finalisation of the deal ... “With a legacy of supporting clinical trials over more than five decades across 130 countries, we remain ...